Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis : a systematic review
Year of publication: |
2024
|
---|---|
Authors: | Gallehzan, Nasrin Abulhasanbeigi ; Khosravinik, Majid ; Jamebozorgi, Khosro ; Mir, Nazanin ; Jalilian, Habib ; Soleimanpour, Samira ; Hoseini, Saeed ; Rezapour, Aziz ; Eshraghi, Abbas |
Published in: |
Health economics review. - Heidelberg : Springer, ISSN 2191-1991, ZDB-ID 2634483-X. - Vol. 14.2024, 1, Art.-No. 12, p. 1-37
|
Subject: | Cost-effectiveness analysis | Cost-utility analysis | Disease-modifying drugs | Relapsing-remitting multiple sclerosis | Kosten-Wirksamkeits-Analyse | Kosten-Nutzen-Analyse | Cost-benefit analysis | Arzneimittel | Pharmaceuticals | Krankheit | Disease | Gesundheitskosten | Health care costs | Gesundheitsökonomik | Health economics |
-
Lazzaro, Carlo, (2025)
-
Cost-effectiveness and estimated health benefits of treating patients with vitamin D in pre-dialysis
Snyder, Sophie, (2020)
-
Kamolpat Chaiyakittisopon, (2021)
- More ...
-
Kelsey, Darren, (2017)
-
Hospitals’ Readiness to Implement Clinical Governance
Ebadi Fardazar, Farbod, (2015)
-
Cost of lung cancer in East Azerbaijan province, in Iran, in 2017
Mir, Habibeh, (2020)
- More ...